Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, references the ENESTop 192-week study results in which treatment-free remission was achieved in patients with chronic myeloid leukemia in chronic phase after stopping second-line nilotinib.
Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Jefferson University, discusses how pharmacists can counsel geriatric patients who may be taking multiple medications for chronic illnesses during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
The Impassion130 trial evaluated whether atezolizumab plus nanoparticle albumin-bound paclitaxel increased overall survival in patients with triple negative breast cancer when compared to chemotherapy alone.
During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.
Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, discusses his recommendations for pharmacists who may be counseling a patient with chronic myeloid leukemia during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
For some patients, stereotactic body radiation therapy may provide an enhanced quality of life, better efficacy, and reduced adverse effects.
Top news of the day from across the health care landscape.
Findings presented at the 2019 ASCO meeting show venetoclax plus obinutuzumab induced deep, high, and long-lasting minimal residual disease negativity in chronic lymphocytic leukemia.
At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.
Top news of the day from across the health care landscape.
Researchers studied the quality of life, pain, Global Health Status, and adverse effects.
A study investigates whether a high-dose of vitamin D with or without exercise is a safe, effective option to prevent bone loss.
Expanded Medicare under the Affordable Care Act nearly eliminated racial disparities in access to timely cancer treatment between African American and white patients.
Daily servings of fruits, vegetables, and grains associated with a lower risk of death from breast cancer.
An abstract presented at the 2019 American Society of Clinical Oncology Annual Meeting showed end-of-study analysis results of the phase 3 CLEOPATRA trial.
Specialty Pharmacy Times® is on site at the American Society of Clinical Oncology Annual Meeting to provide you with coverage of the conference in real time.
Nearly half of evaluable patients with rare central nervous system tumors, neuroblastoma, or other solid tumors had responses to entrectinib.
Lowest test dose of oxaliplatin and capecitabine was comparable to the highest dose in delaying advanced gastroesophageal cancer progression and minimizing adverse effects.
Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.
Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.
A ‘fail-first’ policy by the Centers for Medicare and Medicaid Services could be a nightmare for patients with cancer, according to the Community Oncology Alliance.
Many patients with pancreatic cancer do not receive cancer-directed treatment that may extend survival.
Top news of the day from across the health care landscape.
Genomic data may improve the selection of more precise models for metastatic breast cancer research.
National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice is the first nationwide precision oncology trail for patients with cancers that have not responded to standard treatments.
Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
Using real-time data helped providers identify racial disparities in cancer treatment and narrow the gap in treatment completion rates between white and black patients.
Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains the role of genomics in prostate cancer.
Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.
Top news of the week from Specialty Pharmacy Times.
